Karyopharm Therapeutics (KPTI) PT Lowered to $7 at Piper Sandler
Tweet
Share
E-mailGet Alerts KPTI Hot Sheet
Price: $1.79 --0%
Rating Summary:
11 Buy, 6 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 21 | Down: 20 | New: 24
Rating Summary:
11 Buy, 6 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 21 | Down: 20 | New: 24
Join SI Premium – FREE
Piper Sandler analyst Edward A. Tenthoff lowered the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $7.00 (from $16.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Morgan Stanley Upgrades M&T Bank (MTB) to Overweight
- Sandoz Group AG (SDZ:SW) PT Raised to CHF93 at Barclays
- Sartorius Stedim Biotech (DIM:FP) (SDMHF) PT Raised to EUR240 at Barclays
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
